{"prompt": "['MK-7902', 'PAGE 10', 'PROTOCOL NO.007-05 (E7080-G000-314)', 'Supplemental SAP', '15JUL2021', 'TTD as measured by each of the EORTC QLQ-C30 global health status/QoL, physical', 'functioning, and dyspnea scores, and EORTC QLQ-LC13 cough and chest pain scores.', 'TTD as measured by a composite symptom endpoint: cough (QLQ-LC13 item 31), chest pain', '(QLQ-LC13 item 40), or dyspnea (QLQ-C30 item 8)', 'Based on prior literature (Osoba D et al., 1998; King et al., 1996, Maringwa et al., 2011), a >10', 'point or greater worsening from baseline for each scale represents a minimally important', 'difference (MID) that represents a clinically relevant deterioration. TTD in the individual scores', 'specified above is defined as the time to first onset of >10 (out of 100) point deterioration from', 'baseline in a given scale/subscale/item and confirmed by a second adjacent >10 point', 'deterioration from baseline. TTD in the composite endpoint is defined as the time to first onset of', 'point deterioration (i.e., increase in score) from baseline in any one of the 3 lung cancer', 'symptom scale items (EORTC-QLQ-C30 [dyspnea] and EORTC-QLQ-LC13 [cough and chest', 'pain]) with confirmation by the subsequent visit of a >10 point deterioration (i.e., increase in', 'score) from baseline in the same scale as the first onset. Changes from baseline in EORTC QLQ-', 'C30 scores will also be interpreted according to recent subscale-specific guidelines, which', 'indicate that clinically meaningful differences vary by scale (Cocks et al., 2012)', 'Exploratory', 'Change from baseline in the additional scales of the EORTO QLQ-C30, EORTC QLQ-LC13,', 'and EuroQoL EQ-5D visual analogue scale (VAS) scores. Specifically:', 'Each EORTC QLQ-C30 functional scales: role functioning, emotional functioning,', 'cognitive functioning, and social functioning', 'Each of three EORTO QLQ-C30 symptom scales (fatigue, nausea/vomiting, and', 'pain), and single item measures (sleep disturbance, appetite loss, constipation,', 'diarrhea, and financial difficulties)', 'Each EORTO QLQ-LC13 item: site-specific pain (pain in arm or shoulder, and pain', 'in other parts), sore mouth, dysphagia, peripheral neuropathy, alopecia, and', 'hemoptysis', 'The EQ-5D VAS', 'Proportions of improvement / stability / stability + improvement / deterioration in EORTC', 'QLQ-C30 global health status / QoL, physical functioning, and dyspnea scores, and EORTO', 'QLQ-LC13 cough and chest pain scores where', 'Improvement', 'Improvement for the global health status/QoL and physical functioning scores is', 'defined by an increase of 10 points or more in score from baseline at any time', 'during the study and confirmed by an increase of 10 points or more in score at', 'the next consecutive visit.', 'Confidential']['MK-7902', 'PAGE 11', 'PROTOCOL NO.007-05 (E7080-G000-314)', 'Supplemental SAP', '15JUL2021', 'Improvement for the dyspnea, cough, and chest pain scores is defined by a', 'decrease of 10 points or more in score from baseline at any time during the study', 'and confirmed by a decrease of 10 points or more in score at the next consecutive', 'visit.', 'Stability is defined as follows, when the criteria for improvement are not met:', 'an improvement confirmed by a less than 10 points change from baseline at', 'the next consecutive visit', 'less than 10 points change in score confirmed by a less than 10 points change', 'in score at the next consecutive visit', 'less than 10 points change in score and confirmed by an improvement at the', 'next consecutive visit', 'Stability + improvement is defined as the sum of proportions with stability and', 'improvement as specified above.', 'Deterioration is defined as a 10 points or greater worsening from baseline at any time', 'during the study when the criteria for improvement or stability are not met.', '3.5. Analysis Populations', '3.5.1.', 'Efficacy Analysis Populations', 'The analyses of the primary efficacy endpoints are based on the ITT population. All randomized', 'participants will be included in this population. Participants will be analyzed in the treatment', 'group to which they were randomized. Based on actual enrollment, all participants who were', 'randomized on or prior to January 28, 2021 will be included in the ITT population of the global', 'study. All participants who failed screening in addition to all randomized participants on or prior', 'to January 28, 2021will be included in the screening population. Details on the approach to', 'handling missing data are provided in Section 3.6.', '3.5.2.', 'Safety Analysis Populations', 'Safety analyses will be conducted in the APaT population, which consists of all randomized', 'participants who received at least 1 dose of study intervention. Participants will be included in', 'the treatment group corresponding to the study intervention they actually received for the', 'analysis of safety data using the APaT population. This will be the treatment group to which they', 'are randomized, except for participants who take incorrect study intervention for the entire', 'treatment period; such participants will be included in the treatment group corresponding to the', 'study intervention actually received. Any participant who receives the incorrect study', 'intervention for 1 cycle, but receives the randomized treatment for all other cycles, will be', 'analyzed according to the randomized treatment group, and a narrative will be provided for any', 'events that occur during the cycle for which the participant is incorrectly dosed.', 'Confidential']\n\n###\n\n", "completion": "END"}